Shaoxing Shangyu People's Hospital, Shaoxing 312300, China.
Contrast Media Mol Imaging. 2022 Aug 11;2022:1415659. doi: 10.1155/2022/1415659. eCollection 2022.
In order to explore the efficacy and prognostic value of best corrected visual acuity (BCVA), central macular retinal thickness (CMT), and cystoid macular edema (CME) in diabetic retinopathy (DR) sufferers based on surgical therapy combined with vascular endothelial growth factor (VEGF) therapy at different times, a total of 170 cases of DR sufferers who visited our hospital from March 2019 to March 2021 are analyzed. All patients are randomly divided into control group and study group, with 85 cases and 85 eyes in each group. In addition, the contrast set received 2 therapies for 1.5 months/time, and the study set received 3 therapies for 1 month/time. The experimental results show that the BCVA of the two sets is notoriously enhanced. Besides, CMT and CME in the study set decrease more than those in the contrast set, and the blood vessel density of retinal capillaries in the contrast set and the examination set is notoriously enhanced. For DR sufferers, 1 month/time of anti-VEGF therapy can effectively enhance the sufferers' visual acuity, CMT and CME. It is suggested that the clinical application of 1 month/time of anti-VEGF to DR sufferers can enhance the clinical therapeutic effect of sufferers and reduce the prognosis and recurrence.
为了探索手术治疗联合血管内皮生长因子（VEGF）治疗不同时间点对糖尿病视网膜病变（DR）患者最佳矫正视力（BCVA）、中心黄斑视网膜厚度（CMT）和囊样黄斑水肿（CME）的疗效和预后价值，对 2019 年 3 月至 2021 年 3 月我院收治的 170 例 DR 患者进行了分析。所有患者均随机分为对照组和研究组，每组 85 例，85 只眼。另外，对比组接受 2 次治疗，每次 1.5 个月，研究组接受 3 次治疗，每次 1 个月。实验结果表明，两组的 BCVA 均明显提高。此外，研究组的 CMT 和 CME 下降幅度大于对照组，视网膜毛细血管血管密度在对照组和研究组均明显升高。对于 DR 患者，1 个月/次的抗 VEGF 治疗能有效提高患者视力、CMT 和 CME。建议将 1 个月/次的抗 VEGF 应用于 DR 患者，可提高患者的临床治疗效果，降低预后和复发的风险。
